Inmune Bio Revises Warrant Terms in Strategic Financial Move

In a strategic maneuver aimed at enhancing its financial flexibility, biotechnology firm Inmune Bio has modified the terms for a significant portion of its outstanding warrants. The adjustment is designed to make the securities more appealing to holders and could potentially unlock additional liquidity for the company’s operations.

The company’s financial standing, as of September 30, 2025, shows cash and equivalents of approximately $27.7 million. Its operational burn rate for the third quarter included $4.9 million allocated to research and development efforts, alongside $2.5 million in general and administrative expenses.

Investor attention remains partly focused on recent clinical data. Earlier this month, Inmune Bio presented new imaging results from a Phase 2 study Read more...